Drug Profile
Research programme: fatty acid amide hydrolase inhibitors - Vernalis
Latest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator Vernalis
- Class
- Mechanism of Action Fatty acid amide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in United Kingdom
- 17 Mar 2011 This programme is still in active development